Healthcare Asia’s business portfolio consists of a wide array of products in different oncology areas, stemming from its strong partnerships with suppliers in Europe and United States. Healthcare Asia monitors the list of new FDA-approved drugs closely to keep up with the ever-changing environment of the pharmaceutical industry.
The extensive range includes drugs such as but not limited to:
-
Bladder Cancer Drugs
-
Bone Cancer Drugs
-
Breast Cancer Drugs
-
Leukemia Drugs
-
Liver Cancer Drugs
-
Lung Cancer Drugs
-
Prostate Cancer Drugs
-
Rhabdomyosarcoma Drugs
-
Skin Cancer Drugs
-
Soft Tissue Sarcoma Drugs
-
Thyroid Cancer Drugs
-
Non Small Cell Cancer Drugs
-
Newly approved FDA / EMA Drugs